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Abstract
Background: In January 2010, the American Diabetes Association recommended the use of hemoglobin A1c
(Hgb A1c) to screen and diagnose diabetes. This study explored the prevalence and clinical context of Hgb A1c
tests done for non-diabetic primary care patients for the three years prior to the release of the new guidelines.
We sought to determine the provision of tests in non-diabetic patients age 19 or over, patients age 45 and
over (eligible for routine diabetes screening), the annual change in the rate of this screening test, and the
patient characteristics associated with the provision of Hgb A1c screening.
Methods: We conducted a retrospective study using data routinely collected in Electronic Medical Records. The
participants were thirteen community-based family physicians in Toronto, Ontario. We calculated the proportion of
non diabetic patients who had at least one Hbg A1c done in three years. We used logistic generalized estimating
equation with year treated as a continuous variable to test for a non-zero slope in yearly Hbg A1c provision. We
modelled screening using multivariable logistic regression.
Results: There were 11,792 non-diabetic adults. Of these, 1,678 (14.2%; 95%CI 13.6%-14.9%) had at least one Hgb
A1c test done; this was higher for patients 45 years of age or older (20.2%; 95% CI 19.3% - 21.2%). The proportion
of non-diabetic patients with an A1c test increased from 5.2% in 2007 to 8.8% in 2009 (p < 0.0001 for presence of
slope). Factors associated with significantly greater adjusted odds ratios of having the test done included
increasing diastolic blood pressure, increasing fasting glucose, increasing body mass index, increasing age, as well
as male gender and presence of hypertension, but not smoking status or LDL cholesterol. Patients living in the
highest income quintile neighbourhoods had significantly lower odds ratios of having this test done than those in
the lowest quintile (p < 0.001).
Conclusions: A large and increasing proportion of the non-diabetic patients we studied have had an Hgb A1c for
screening prior to guidelines recommending the test for this purpose. Several risk factors for cardiovascular disease or
diabetes were associated with the provision of the Hgb A1c. Early uptake of the test may represent appropriate
utilization.
Background
Diabetes is an increasingly prevalent condition in Canada,
with serious effects on morbidity and mortality [1]. This
condition can be present for up to seven years prior to
diagnosis [2], leading to recommendations for periodic
screening of asymptomatic individuals [1,3,4].
Guideline recommendations regarding screening and
diagnosis of diabetes are currently evolving. In 2009 the
use of hemoglobin A1c (Hgb A1c), which represents an
index of the average plasma glucose level over several
weeks, was recommended by an international committee
for the diagnosis of diabetes [5]. In 2010, the American
Diabetes Association (ADA) agreed [3,4,6]. The ADA
suggested that Hgb A1c be considered as an acceptable
test to diagnose diabetes, with a confirmed value of 6.5%
or greater being diagnostic [3].
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do not recommend Hgb A1c for screening or diagnosis.
Fasting Blood Glucose (FBG) is recommended for screen-
ing [1], and diagnosis depends on repeated elevated
glucose tests or an abnormal Oral Glucose Tolerance Test
(OGTT) [1]. However, the OGTT is not often used in
Ontario [7]; it is inconvenient for patients and more vari-
able than fasting blood glucose or Hgb A1c [8]. Hgb A1c
may be a better test for screening than FBG because it is
more replicable [9], and offers superior prognostic value
for neuropathy, retinopathy [9], and cardiovascular disease
[10]. Hgb A1c is equal to FBG as a predictor of diabetes
[10], but is more convenient than FBG because it does not
require fasting. However, Hgb A1c is more costly [11], and
may be inaccurate in the setting of hemoglobinopathies
[3]. As well, normal Hgb A1c levels may be higher in
black persons [12].
Despite the lack of any guideline-based recommenda-
tions at the time, 6.0% of adults without diabetes had a
Hgb A1c done (presumably for diabetes screening) in
Ontario in 2005 [7]. While this does suggest that Hgb A1c
is commonly used for screening in this context, the study
was limited by the secondary use of administrative data,
which lacks clinical information including laboratory
values. The investigators could not identify several ele-
ments underlying the clinical context of these tests.
Therefore, we used electronic medical records (EMRs)
of community based family physicians to investigate the
prevalence and clinical context of Hgb A1c tests done for
patients without diabetes prior to the release of the new
guidelines. We examined the change in rates of Hgb A1c
over the three years preceding the release of the 2010
ADA guidelines. In order to explore patient characteristics
associated with early adoption of the Hgb A1c test for
screening purposes, we extracted information on a variety
of clinical risk factors associated with increased cardiovas-
cular risk or diabetes from data available in the EMRs.
Methods
Participants
The Canadian Primary Care Sentinel Surveillance Network
(CPCSSN) is Canada’s first multi-disease EMR-based
surveillance system [13]. The North Toronto Research
Network (NorTReN) is one of nine networks currently
participating in CPCSSN. NorTReN is a practice based
primary care research network affiliated with the Depart-
ment of Family and Community Medicine at the University
of Toronto. Family physicians participating in NorTReN
contribute their EMR data; an anonymized version of
applicable data is sent to CPCSSN’s central data repository
from each site and is then de-identified and aggregated in a
single national database. Posters informing patients about
the study are present in the waiting rooms of participating
practices, and patients can opt out. One patient has opted
out of the NorTReN database, while 111 patients have
opted out of the national CPCSSN database.
We obtained data from the Electronic Medical Records
(EMRs) of community based family physicians in Toronto,
Ontario. Thirteen family physicians participating in NorT-
ReN who had used an EMR for three years or more and
who currently contribute data to CPCSSN were included
in this study. All physicians were community-based, were
members of a Family Health Team [14], and had rostered
practices in which patients formally enrolled with their
physician, allowing the identification of practice panels
[15,16]. A Family Health Team consists of a group of
physicians paid largely by capitation (a set fee based on
rostered patients’ age and gender); physicians work in
multidisciplinary practices, along with nurses, social work-
ers and other allied health professionals. The physicians in
this study used a single EMR (Nightingale on Demand
®).
Eligible patients and determination of diabetic status
The eligible population included all non-diabetic rostered
patients age 19 and over who had seen their family physi-
cian at least once between January 1
st 2007 and December
31
st 2009 and were active as of December 31
st 2009.
In order to capture tests that were ordered for screening
purposes (and not for disease monitoring), we identified
and excluded all known diabetic patients. To define dia-
betes, we followed a previously validated algorithm for
administrative databases [17] and used two billing codes
for diabetes in two years. This algorithm only had a sensi-
tivity of 86% [17]. However, we are able to access data
unavailable in administrative databases; our definition
added the presence of diabetes in the problem list and we
used free-text search terms that would likely maximize the
number of true positives for the diagnosis of diabetes. If
neither billing nor problem list data were present, we then
searched for the presence of any current hypoglycemic
medication (insulins, sulfonylureas, metformin, thiazolidi-
nediones, incretins, or acarbose), or for an Hgb A1c of 7%
or greater, or two fasting blood glucose tests of 7 mmol/l
or greater [1]. We then manually excluded patients with
polycystic ovarian syndrome (metformin can be used clini-
cally for ovulation induction and management of meta-
bolic syndrome in PCOS) [18-20], gestational diabetes,
secondary diabetes, and hyperglycemia not otherwise spe-
cified based on coding for these conditions. The approach
is similar to that of a validated algorithm using EMR data
[21]. Further development of electronic data queries for
case definitions had been undertaken as part of CPCSSN
[13].
Laboratory screening increases with age [22]. Screening
in younger age ranges is recommended only for patients
deemed to be at higher risk of chronic diseases [1,4,11,23].
This may confound our comparisons of the screened and
non-screened groups as screening in general may be more
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present descriptive data restricted to those age 45 and
over by December 31
st 2009. By that age, both Canadian
and American guidelines recommend diabetic screening
for patients at low risk [1,4]. Patients presenting for a peri-
odic health exam may be more likely to have screening
blood work [22,24,25], as are those with a chronic health
condition. There may be systematic differences between
those having screening bloodwork and those not having
this done [22]. We used the presence of total cholesterol
in the past three years as a marker of a blood test done for
screening [22,26] or chronic cardiovascular disease man-
agement. We then also calculated the proportion of
screening Hgb A1c tests done for patients age 45 or over
who had at least one total cholesterol done, that is those
presumed to have presented for screening bloodwork.
Data elements
We extracted values for Hgb A1c, as well as for data asso-
ciated with cardiovascular risk factors [26-29]. The follow-
ing data elements, if present in the EMR in the past
three years (January 1 2007 to December 31 2009), were
extracted: age in years, gender, current smoking status (if
available in the patient’s health profile), Hgb A1c, LDL
cholesterol, fasting glucose levels, weight, BMI, waist cir-
cumference and blood pressure. Age was calculated as
‘test done date’ minus July 1, birth-year for all patients
with Hgb AIc test done. For those without an Hgb A1C
test, age was calculated as ‘study end date’ of December
31
st 2009 minus July 1, birth-year for all patients. For
laboratory measurements, we chose the value occurring
immediately prior to the screening Hgb A1c test. If some-
one was screened on multiple occasions, we considered
time of most recent screen and determined values of pre-
dictors from this time point. For patients that were never
screened, we considered values of the predictors from the
most recent time point. The Postal Code Conversion File
was used to assign neighbourhood income quintile to the
patients’ residential postal code.[15]
Data completeness in EMRs used in routine care may be
problematic, as clinicians may neglect to enter data or
data may be entered in fields that are not captured during
searches; some laboratory tests may not be received elec-
tronically [30]. To give an indication of data completeness
we have included the percentage of missing values by
study variable and patient group in the results section.
Analysis
We first calculated the proportion of non-diabetic
patients who had at least one Hbg A1c done in the past
three years. We then calculated the proportion of
patients with at least one Hgb A1c test in each year of
interest. We used logistic generalized estimating equation
with year treated as a continuous variable to test for a
non-zero slope in Hbg A1c provision.
We compared characteristics of patients age 45 and
over who did and did not have at least one Hgb A1c in
the three years of interest. We used descriptive statistics
such as means, medians, ranges, standard deviations and
percentages to summarize baseline data. Logistic regres-
sion was used to identify clinically relevant factors asso-
ciated with Hgb A1c testing [31]. First, we considered
odds ratios and p values for each of the univariate predic-
tors of screening. We then modelled screening (multi-
variable/adjusted model) as a function of various
biochemical, demographic and behavioural covariates. All
tests were two tailed and p value of < 0.05 was considered
statistically significant. We used SAS version 9.2 for the
analysis and data manipulation.
This study was approved by the North York General
Hospital’s Research Ethics Board. All physicians pro-
vided signed, informed consent.
Results
Thirteen family physicians contributed data. The mean
year of graduation was 1981, with a range of 1967 to
2002. Five physicians were male, and twelve were Cana-
dian graduates.
The number of active rostered patients age 19 and over
was 13,112, and,11,792 patients (89.9%) were not dia-
betic. Of these non-diabetic patients, 1,678 (14.2%; 95%
CI 13.6% - 14.9%) had at least one Hgb A1c test done in
the three year period prior to the release of the new ADA
guidelines. The percentage of non-diabetic adults
who had a Hgb A1c done was 5.2% in 2007, 7.5% in 2008
and 8.8% in 2009; the presence of a slope was significant
(p < 0.0001).
There were 6,786 non-diabetic patients age 45 or
more; 1,372 (20.2%; 95% CI 19.3% - 21.2%) of those
patients had a screening Hgb A1c done. Limiting to
those patients who had screening blood work (based on
presence of a total cholesterol value in the chart),
resulted in 4,863 patients, of whom 1,298 (26.7%; 95%
CI 25.5% - 27.9%) had a screening Hgb A1c.
The characteristics of patients age 45 and over are
presented in Table 1. 81.8% of patients with a Hgb A1c
present were age 45 and over, and 94.6% of those
patients had at least one total cholesterol value in the
chart. The median age for patients who had a screening
Hgb A1c was 63 (IQR 55 - 73), while median age for
those without the test was 57 (IQR 50 - 68). One-fifth
(19.8%) of those screened had fasting blood glucose in
the impaired range (6.0 - 6.9 mmol/L), while 5.4% of
those not screened had a value in this range. Nearly half
(47%) of those screened were hypertensive, compared to
30% of those not screened.
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ple, 5% of those screened with Hgb A1c did not have a
LDL cholesterol value during the three years for the
measures we obtained, while 28% of those not screened
had no value. Missing vital signs (other than waist cir-
cumference) ranged from 5% to 8% in those screened,
and from 9% to 14% in those not screened.
Table 2 depicts the bivariate odds ratios associated with
each possible predictor of being screened for patients age
45 and over. Increasing BMI, increasing waist circumfer-
ence, increasing fasting glucose, increasing blood pressure,
increasing age, male gender and presence of hypertension
were associated with significantly greater bivariate odds
ratios for being screened with Hgb A1c. Patients living in
the highest income neighbourhood had significantly lower
odds ratios compared to patients living in the lowest
income neighbourhood for being screened. Smoking status
was not associated with significantly different odds ratios
for being screened with Hgb A1c.
The multivariable/adjusted model is presented on
table 3. It includes those factors found to be significant
in the bivariate regression analysis, with the exception
of LDL cholesterol and waist circumference. LDL cho-
lesterol was excluded due to its marginal significance in
the bivariate regression, while waist circumference was
dropped from the model due to the high proportion of
missing results. In the adjusted model, increasing dia-
stolic blood pressure, increasing fasting glucose, increas-
ing BMI, increasing age, as well as male gender and
presence of hypertension were significantly associated
with adjusted odds ratios of having a Hgb A1c done.
Patients living in the highest income quintile neighbour-
hoods had significantly lower odds ratios of having this
test done than those in the lowest income quintile.
Discussion
The physicians in this study began using the Hgb A1c test
for some non-diabetic patients well before the release of
the guidelines; we found that a fifth of patients without
diabetes age 45 or more had at least one Hgb A1c done in
a three year period. The proportion of patients with an
Hgb A1c test increased over time. It is encouraging to
note that patients were more likely to be screened if they
had clinical risk factors associated with diabetes, such as
increasing age, higher fasting blood glucose, higher BMI,
or presence of hypertension. In such patients, it is possible
that Hgb A1c was added to fasting blood glucose to aug-
ment the detection of diabetes. The combination of the
two tests can determine the presence of diabetes with
greater sensitivity than a single test [32], but the effective-
ness and cost-effectiveness of this approach is unknown
[7].
Interestingly, female patients and patients at the high-
est socioeconomic levels had significantly lower odds
ratios for being screened. A population-based study
tracking Ontarians from 2000-2006 similarly found that
non-diabetic patients were more likely to be screened
w i t hab l o o dg l u c o s ei ft h e yw e r eh y p e r t e n s i v e ,h a d
Table 1 Patient characteristics, limited to patients who were at least 45 years old
Total non-diabetic patients* Non-diabetic patients without a
screening Hgb A1c from 2006 to
2009
Non-diabetic patients with at
least one screening Hgb A1c
from 2006 to 2009
Parameter Value % with no data Value % with no data Value % with no data
N (%) 6786(100) 5414(80) 1372(20)
% Male 34 0 33 0 44 0
Mean age in years (median, IQR) 61 (59, 51-70) 0 60 (57, 50-68) 0 64 (63, 55-73) 0
% current smoker 71 0 7 1 2 8 5
Mean weight in Kg (SD) 73.3(17.1) 11 72.1(16.7) 13 77.0(17.9) 6
Mean BMI** (SD) 26.9(5.2) 13 26.5(5.0) 14 28.0(5.6) 8
%BMI > = 30 21 19 29
Mean WC in cm (SD) 90 (14) 67 89 (13) 66 96 (12) 70
Mean sBP in mmHg (SD) 123(15) 8 123(15) 9 125 (15) 5
Mean dBP in mmHg (SD) 76 (9) 8 75(9) 9 77(9) 5
% Patients with HTN 34 30 47
Mean LDL cholesterol in mmol/l (SD) 3.3(0.9) 23 3.3(0.9) 28 3.2(1.0) 5
Mean FBG in mmol/l (SD) 5.3(0.6) 23 5.2 (0.5) 29 5.5(0.6) 4
% with FBG 6 to 6.9 8.7 5.4 19.8
*Patients indicated as being active and rostered to a participating physician on December 31




**BMI: Body mass index (weight in kilograms divided by height in meters squared).
WC: waist circumference; sBP: sytolic blood pressure; dBP: diastolic blood pressure; HTN: hypertension; FBG: fasting blood glucose; SD: standard deviation; IQR:
interquartile range.
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women were more likely to be screened than men [33].
The population-based analysis also found that the rate
of Hgb A1c testing for non-diabetic patients in Ontario
was rapidly increasing, and had reached 6.0% by 2005.
In our study population, the rate was 8.8% in 2009. It is
unclear if our findings represent unique features of our
study population or changes over time in the utilization
Table 2 Bivariate results from logistic regression analysis of HgBA1C screening limited to patients who were at least
45 years old
OR 95% CI (OR) P-value Sample Size (N)
LDL cholesterol 0.93 0.86 - 0.99 0.04 4,830
BMI 1.06 1.04 - 1.07 < 0.0001 5,192
Waist Circumference 1.05 1.04 - 1.06 < 0.0001 1,952
Systolic blood pressure 1.01 1.01 - 1.01 < 0.0001 5,619
Diastolic blood pressure 1.02 1.01 - 1.03 < 0.0001 5,614
Fasting blood glucose 2.66 2.36 - 3.00 < 0.0001 4,811
Age 1.03 1.02 - 1.03 < 0.0001 6,786
Sex
￿ Female —— — —
￿ Male 1.77 1.57 - 1.99 < 0.0001 6,786
Smoking Status
￿ Current smoker —— — —
￿ Ex-Smoker 1.22 0.95 - 1.57 0.12 6,088
￿ Never Smoked 0.94 0.75 - 1.19 0.62
Hypertension
￿ No —— — —
￿ Yes 2.15 1.91 - 2.43 < 0.0001 6,786
Neighborhood income quintile*
￿ 1 —— — —
￿ 2 0.81 0.64-1.02 0.07 6,617
￿ 3 0.90 0.73-1.11 0.34
￿ 4 0.75 0.61-0.93 0.007
￿ 5 0.59 0.49-0.73 < 0.0001
* The Postal Code Conversion File was used to assign neighbourhood income quintile to the patients’ residential postal code; 1 indicates the highest income
quintile, while 5 indicates the lowest income quintile
Table 3 Adjusted Odds Ratios for the likelihood of being screened with Hgb A1c
OR 95% CI(OR) P-value
Systolic blood pressure 0.99 0.98 - 0.99 < 0.0001
Diastolic blood pressure 1.03 1.02 - 1.04 < 0.0001
Fasting blood glucose 2.22 1.91 - 2.57 < 0.0001
BMI 1.03 1.01 - 1.05 0.0002
Age 1.03 1.02 - 1.04 < 0.0001
Sex
￿ Female —— —
￿ Male 1.55 1.31 - 1.82 < 0.0001
Hypertension
￿ No —— —
￿ Yes 1.31 1.10 - 1.56 0.003
Neighborhood income quintile
￿ 1 —— —
￿ 2 0.69 0.51 - 0.93 0.02
￿ 3 0.83 0.63 - 1.10 0.20
￿ 4 0.81 0.61 - 1.06 0.13
￿ 5 0.63 0.48 - 0.82 0.001
Greiver et al. BMC Family Practice 2011, 12:91
http://www.biomedcentral.com/1471-2296/12/91
Page 5 of 7of Hgb A1c. Regardless, it seems likely that Hgb A1c
utilization will accelerate if/when Canadian guidelines
recommending Hgb A1c for screening are disseminated.
Limitations
This study is limited to community-based family physi-
cians participating in a Practice Based Research Network
in Toronto and using a single EMR; results may not be
applicable to other settings or other EMRs. Nevertheless,
there is no a priori reason to believe that the use of Hgb
A1c for screening would be systematically different in
this group of physicians; therefore we believe the results
from this study provide valuable insight into the gradual
increase in Hgb A1c utilization.
Our criteria for determining the presence of diabetes are
similar to those others have employed, but have not been
formally validated. Validation of chronic disease criteria in
the CPCSSN database is ongoing. Furthermore, we could
not reliably include patients with an Hgb A1c of 7% or
more into the screened cohort because data in the EMR
were not complete enough to allow us to determine
whether the diagnosis of diabetes existed prior to the test.
Thus, there was uncertainty as to whether they were
screened or monitored. Including patients with a Hgb A1c
of 7% or more in the screening group would have inflated
our results.
EMR data abstracted for this study were fairly com-
plete, but there were differences in missing data
between the populations screened and not screened
w i t hH g bA 1 c .N e a r l ya l l( 9 5 % )o fp a t i e n t sa g e4 5o r
over with a Hgb A1c screen had a LDL cholesterol pre-
sent in the EMR. However, only 72% of those without
Hgb A1c had at least one LDL cholesterol level present
in the three years studied. We have no reasons to
assume that rates of missing EMR data (test done, but
data not present in an electronically auditable form) are
different between the two groups, so it is possible that
s o m ep a t i e n t sd i dn o th a v eaH g bA 1 cd o n es i m p l y
because they did not present for any screening blood
work.
This study examined factors extensively documented in
the literature as being associated with cardiovascular risk
factors [26-29] and clinically likely to influence a family
physician’sr i s ke s t i m a t i o n .T h e r ea r eal a r g en u m b e ro f
data elements in the EMR, and we wished to be conserva-
tive in order to exclude spurious associations that could
be significant due to the large sample size. Therefore, we
did not include LDL cholesterol in the model because it
had only marginal statistical association and limited clini-
cal plausibility. It is possible that consideration of other
variables for the model may have altered the results, but
in a sensitivity analysis, we included triglycerides and this
did not change our findings.
Conclusions
Hgb A1c screening was provided to patients by these
community-based family physicians prior to the release
of guidelines recommending the use of this test for
screening purposes. The rates of screening increased
over time. Patients screened had several clinical factors
associated with greater risks of cardiovascular disease
and diabetes, indicating that the utilization of Hgb A1c
for screening in this group was frequently appropriate.
The incidence and prevalence of diagnosed diabetes
may change due to the rising use of Hgb A1c screening
and the introduction of Hgb A1c of 6.5% or greater as a
new criterion for diagnosis [3]. In Ontario, it is estimated
that 1.4% of the population is undiagnosed [33]. Should
Canadian guidelines concur with American guidelines, a
proportion of the undiagnosed practice populations
could be immediately identified using data already pre-
sent in the EMRs.
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